Efficacy and safety of QL0911 in adult patients with chronic primary immune thrombocytopenia: A multicenter, randomized, double-blind, placebo-controlled, phase III trial

医学 安慰剂 罗米普洛斯蒂姆 内科学 临床终点 不利影响 血小板生成素 脾切除术 随机对照试验 胃肠病学 血小板 外科 替代医学 脾脏 干细胞 病理 造血 生物 遗传学
作者
Hu Zhou,Shouqing Han,Jie Jin,Ruibin Huang,Xinhong Guo,Xuliang Shen,Binghua Wang,Xin Wang,Hongxia Yao,Xin Du,Meijuan Huang,Xuehong Ran,Wei Wang,Tonghua Yang,Feng Zhang,Changcheng Zheng,Xuelan Zuo,Rong Fu,Da Gao,Zheng Ge
出处
期刊:Journal of Translational Internal Medicine [De Gruyter]
卷期号:11 (4): 423-432 被引量:17
标识
DOI:10.2478/jtim-2023-0106
摘要

Abstract Objective QL0911, a recombinant human thrombopoietin mimetic peptide-Fc fusion protein, is a romiplostim (Nplate ® ) biosimilar used to treat primary immune thrombocytopenia (ITP). This phase III study aimed to assess the efficacy and safety of QL0911 in adult patients with chronic primary ITP over a 24-week treatment period. Methods We conducted a double-blind, placebo-controlled, phase III study in patients diagnosed with primary ITP for at least 12 months who had received at least one first-line ITP treatment with no response or recurrence after treatment, or who relapsed after splenectomy at 44 sites in China. Patients were randomly allocated (2:1 ratio) to QL0911 or placebo injection subcutaneously once weekly at an initial dose of 1 μg/kg for 24 weeks. The doses were adjusted to maintain the target platelet counts from 50 × 109/L to 200 × 109/L. Patients and investigators were blinded to the assignment. The primary endpoints were the proportion of patients who achieved a durable platelet response at week 24 (platelet count, ≥ 50 × 109/L during 6 of the last 8 weeks of treatment) and safety. The study was registered at ClinicalTrials.gov (NCT05621330). Results Between October 2019 and December 2021, 216 patients were randomly assigned (QL0911,144; placebo,72). A durable platelet response was achieved by significantly more patients in the QL0911 group (61.8%, 95% CI: 53.3-69.8; P < 0.0001) than in the placebo group (0%). The mean duration of platelet responses was 15.9 (SE: 0.43) weeks with QL0911, and 1.9 (SE:0.26) week with placebo. Consistent results were achieved in subgroup analyses categorized by baseline splenectomy status (yes/no), concomitant ITP treatment (yes/no), and baseline platelet count (≤ 10 × 109/L, > 10 × 109/L, ≤ 20 × 109/L, > 20 × 109/L, and < 30 × 109/L). The incidence of TEAEs was comparable between the QL0911 and the placebo groups (91.7% and 88.9%, respectively). The most common adverse events overall were ecchymosis (28.5% for QL0911 vs . 37.5% for placebo), upper respiratory tract infections respiratory tract infections (31.9% for QL0911 vs . 27.8% for placebo), and gingival bleeding (17.4% for QL0911 vs . 26.4% for placebo). Conclusion QL0911 was well-tolerated and increased and maintained platelet counts in adults with ITP. QL0911, a biosimilar to romiplostim (Nplate®), may be a novel treatment option for patients with ITP who have failed or relapsed from first-line treatment in China. Ongoing studies will provide further data on long-term efficacy and safety in such patient populations.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
lihuilisa完成签到,获得积分10
2秒前
管ws完成签到 ,获得积分10
4秒前
嘟嘟豆806完成签到 ,获得积分0
4秒前
半夏不泻心完成签到,获得积分10
5秒前
在九月完成签到 ,获得积分10
6秒前
8秒前
月亮完成签到,获得积分10
9秒前
Nuyoahl完成签到 ,获得积分10
9秒前
易道聚焦完成签到,获得积分10
13秒前
cL完成签到 ,获得积分10
14秒前
littlelitter完成签到,获得积分10
14秒前
科研一坤年完成签到,获得积分10
15秒前
ghshen的应助被16601107082采纳,获得10
17秒前
科研通AI6.4的应助被小李子采纳,获得10
18秒前
怼怼完成签到 ,获得积分10
18秒前
xelloss完成签到,获得积分10
20秒前
Loong完成签到,获得积分10
20秒前
null的应助被littlelitter采纳,获得10
20秒前
智文完成签到 ,获得积分10
23秒前
uus13完成签到,获得积分10
23秒前
Jasper的应助被Xu采纳,获得10
23秒前
向日葵完成签到,获得积分10
23秒前
uus13发布了新的文献求助10
26秒前
26秒前
称心访卉完成签到,获得积分10
28秒前
赤小豆完成签到,获得积分10
30秒前
wangshuai完成签到 ,获得积分10
31秒前
碧蓝的小海豚完成签到 ,获得积分10
31秒前
禾苗完成签到 ,获得积分10
31秒前
夕阳完成签到 ,获得积分10
32秒前
年轻千萍完成签到,获得积分10
34秒前
刻苦的砖头完成签到 ,获得积分10
35秒前
35秒前
哈哈完成签到,获得积分10
36秒前
wali完成签到 ,获得积分0
36秒前
free2030完成签到,获得积分10
36秒前
王梦瑶完成签到 ,获得积分10
36秒前
541完成签到 ,获得积分10
36秒前
舟舟完成签到 ,获得积分10
39秒前
陈槊诸发布了新的文献求助10
41秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Hidden Empire of Finance: How Wall Street Profits from Our Cities and Fuels Global Inequality 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8166556
求助须知:如何正确求助?哪些是违规求助? 9559576
关于积分的说明 21750809
捐赠科研通 7757392
什么是DOI,文献DOI怎么找? 3429167
关于科研通互助平台的介绍 2553530
邀请新用户注册赠送积分活动 2473923